Two randomized, double‐blind, placebo‐controlled studies demonstrated responses (≥ 50
000/μL) to fostamatinib in adults with long‐standing immune thrombocytopenia (ITP). The …

Fostamatinib demonstrated efficacy in phase 3 trials of adults with immune
thrombocytopenia (ITP). Post hoc analysis compared patients who received fostamatinib as …

Spleen tyrosine kinase (Syk) signaling is central to phagocytosis‐based, antibody‐mediated
platelet destruction in adults with immune thrombocytopenia (ITP). Fostamatinib, an oral Syk …

Fostamatinib is a spleen tyrosine kinase inhibitor recently approved for the treatment of
chronic immune thrombocytopenia (ITP) in patients without adequate response to at least 1 …

Introduction Primary immune thrombocytopenia (ITP) is an autoimmune disorder
characterized by a low platelet count (< 100× 109/L) with an increased risk of bleeding …

Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by
phagocytosis and destruction of autoantibody-coated platelets via spleen tyrosine kinase …

Background: Patients with immune thrombocytopenia (ITP) are at risk of bleeding and,
paradoxically, thromboembolic events (TEEs), irrespective of thrombocytopenia. The risk of …

Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder affecting
approximately 1 in 20,000 people. Patients typically present with clinically benign …

Rigel Pharmaceuticals are developing the spleen tyrosine kinase (SYK) inhibitor
fostamatinib (TAVALISSE™) as a treatment for immune thrombocytopenia (ITP) …

Approximately 80% of adult patients with immune thrombocytopenia (ITP) have treatment
failure with corticosteroids or become dependent on them and require second-line therapy …